The type 2 diabetes (T2D) drug market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered because these emerging therapies will be predominantly later-to-market entrants of existing drug classes or combination treatments. Owing to the increased risk of cardiovascular (CV) and kidney disease associated with T2D, a high unmet need exists for affordable drugs that can safely and effectively manage this disease in the long term. The sodium-glucose co-transporter-2 (SGLT-2) inhibitors, such as AstraZeneca’s Farxiga / Forxiga, and glucagon-like peptide-1 (GLP-1) receptor agonists, such as Novo Nordisk’s Ozempic, are offering hope for greater CV and renal benefits. However, the physical and financial impacts of T2D continue to increase, highlighting the need for more-effective and more-affordable drug treatments.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for type 2 diabetes?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for type 2 diabetes?
  • What are the prevailing areas of unmet need and opportunity in type 2 diabetes?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European endocrinologists for a hypothetical new type 2 diabetes drug?

PRODUCT DESCRIPTION

Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 32 European endocrinologists fielded in March 2020

Key companies: AstraZeneca, Eli Lilly, Janssen, Merck, Novo Nordisk

Key drugs: Farxiga / Forxiga, Invokana, Januvia, Jardiance, Rybelsus, Trulicity, Victoza


Related Reports

Type 2 Diabetes - Landscape & Forecast - Disease Landscape & Forecast

View Details

Type 2 Diabetes | Disease Landscape and Forecast | G7 | 2020

The type 2 diabetes therapy market will steadily expand over the 2019-2029 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in th...

View Details

Type 2 Diabetes - Epidemiology - Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key type 2 diabetes patient...

View Details

Type 2 Diabetes - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) Dashboard

Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes drugs and dominate the early lines of therapy, before disease progression requires insulin replacement. The emergence of...

View Details